CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has granted Fast Track Designation for VX-880. VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia.
The company has started a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness. The clinical trial is a phase 1/2, single-arm, open-label study. Approximately 17 patients will be enrolled in the trial.
Copyright RTT News/dpa-AFX
VERTEX PHARMACEUTICALS-Aktie komplett kostenlos handeln - auf Smartbroker.de